Humacyte, Inc. (NASDAQ:HUMA) Sees Large Increase in Short Interest

Humacyte, Inc. (NASDAQ:HUMA) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 3,980,000 shares, an increase of 5.3% from the March 15th total of 3,780,000 shares. Based on an average trading volume of 968,700 shares, the short-interest ratio is presently 4.1 days. Currently, 4.6% of the company’s shares are sold short.

Institutional Trading of Humacyte

A number of institutional investors have recently bought and sold shares of HUMA. Ensign Peak Advisors Inc purchased a new position in Humacyte in the 1st quarter valued at $56,000. American International Group Inc. purchased a new stake in Humacyte during the second quarter worth approximately $27,000. Tower Research Capital LLC TRC boosted its stake in Humacyte by 261.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,989 shares of the company’s stock valued at $26,000 after acquiring an additional 6,504 shares in the last quarter. UBS Group AG increased its position in shares of Humacyte by 92.0% during the third quarter. UBS Group AG now owns 9,827 shares of the company’s stock worth $32,000 after purchasing an additional 4,710 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. purchased a new stake in shares of Humacyte in the 4th quarter valued at about $28,000. 44.71% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 price objective on shares of Humacyte in a report on Monday, April 1st. Piper Sandler reaffirmed a “neutral” rating and issued a $4.00 price objective on shares of Humacyte in a report on Tuesday, March 26th. Finally, Benchmark reissued a “buy” rating and issued a $15.00 target price on shares of Humacyte in a research report on Monday, March 25th.

Humacyte Stock Up 3.9 %

Shares of HUMA stock traded up $0.12 on Wednesday, hitting $3.18. 739,981 shares of the stock were exchanged, compared to its average volume of 968,228. The company has a quick ratio of 4.52, a current ratio of 4.52 and a debt-to-equity ratio of 1.20. The firm’s 50 day moving average is $3.52 and its two-hundred day moving average is $2.97. Humacyte has a one year low of $1.96 and a one year high of $5.60.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Friday, March 22nd. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01. During the same period in the prior year, the company earned ($0.21) EPS. On average, equities analysts expect that Humacyte will post -0.9 earnings per share for the current year.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).